Tirzepatide
Dual GIP/GLP-1 Receptor Agonist — Research Grade
"A dual incretin receptor agonist for advanced metabolic pathway research."
Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide supplied for in vitro and laboratory research use only. Researchers use it to study simultaneous activation of two incretin receptor pathways, complementary metabolic signaling, and receptor co-agonism in controlled experimental models. Not for human or veterinary use.
Contact our research team to discuss purity specifications, available quantities, certificate of analysis, and shipping requirements for your laboratory.
For in vitro laboratory research use only. Not for human or veterinary consumption. A Certificate of Analysis (CoA) is provided with every order.
How It Works
In research settings, tirzepatide enables simultaneous study of GIP and GLP-1 receptor activation, allowing researchers to investigate dual incretin pathway interactions, insulin secretion modulation, glucagon suppression, and energy metabolism signaling in cell-based and biochemical assay systems.
Observed Research Endpoints
- Enables dual incretin receptor co-agonism research
- Supports in vitro studies of complementary metabolic signaling pathways
- Useful for comparative receptor pharmacology studies
- High purity suitable for biochemical and cell-based assays
- Valuable tool for next-generation incretin biology research
Important Considerations
- For laboratory research use only — not for human or veterinary consumption
- Handle with appropriate laboratory safety protocols
- Store under recommended conditions to maintain peptide integrity
- Research use requires qualified personnel and institutional oversight
- Dispose of according to institutional waste management guidelines
Supplied as a research-grade peptide for in vitro laboratory use only. Not intended or suitable for administration to humans or animals. All research applications must comply with applicable regulations.